Drugs / GVAX pancreatic cancer
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02451982 | Mar 2016 → Sep 2026 overdue | malignant pancreatic neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Active not recruiting | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GVAX pancreatic cancer | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02451982 ↗ |
| Action | Activate | “immune system activating pancreatic cancer vaccine” NCT02451982 ↗ |
| Modality | Vaccine | “immune system activating pancreatic cancer vaccine” NCT02451982 ↗ |
| Route | Other | “intradermal injection” NCT02451982 ↗ |